{
  "schemaVersion": "orion-company-promise-record-v1",
  "ticker": "SRRK",
  "company": "Scholar Rock",
  "url": "https://www.orionbiotechai.com/company/SRRK",
  "generatedFrom": "founder-checked batch, as of 2026-10-12",
  "records": [
    {
      "chainId": "SRRK-P2",
      "program": "SRK-439 · topline data",
      "eventLabel": "Clinical results disclosure",
      "status": "Window open",
      "statusDefinition": "https://www.orionbiotechai.com/orion-methodology.html#promise-status-window-open",
      "firstStated": {
        "statement": "SRK-439 Phase 1 trial ongoing in healthy volunteers; topline data expected in H2 2026",
        "window": "in H2 2026",
        "documentType": "SEC Exhibit 99.1",
        "date": "2026-01-12",
        "dateBasis": "filing_date",
        "url": "https://www.sec.gov/Archives/edgar/data/1727196/000110465926002757/srrk-20260112xex99d1.htm"
      },
      "restatements": [
        {
          "kind": "Statement retained",
          "statement": "A Phase 1 study evaluating SRK-439 in healthy volunteers is underway, with topline data expected in the second half of 2026.",
          "window": "in the second half of 2026",
          "documentType": "SEC Exhibit 99.1",
          "date": "2026-03-03",
          "dateBasis": "filing_date",
          "url": "https://www.sec.gov/Archives/edgar/data/1727196/000110465926022547/srrk-20260303xex99d1.htm"
        },
        {
          "kind": "Statement retained",
          "statement": "A Phase 1 study evaluating SRK-439 in healthy volunteers is underway, with topline data expected in the second half of 2026.",
          "window": "in the second half of 2026",
          "documentType": "SEC Exhibit 99.1",
          "date": "2026-05-07",
          "dateBasis": "filing_date",
          "url": "https://www.sec.gov/Archives/edgar/data/1727196/000110465926056655/srrk-20260507xex99d1.htm"
        },
        {
          "kind": "Statement retained",
          "statement": "A Phase 1 study of SRK-439 in healthy volunteers is currently underway, with topline data anticipated in the second half of 2026.",
          "window": "in the second half of 2026",
          "documentType": "SEC Form 10-Q",
          "date": "2026-05-07",
          "dateBasis": "filing_date",
          "url": "https://www.sec.gov/Archives/edgar/data/1727196/000110465926056667/srrk-20260331x10q.htm"
        },
        {
          "kind": "Wording changed",
          "statement": "A Phase 1 study evaluating SRK-439 in healthy volunteers is progressing well with topline data anticipated in late 2026.",
          "window": "in late 2026",
          "documentType": "Company press release",
          "date": "2026-08-06",
          "dateBasis": "company_release",
          "url": "https://investors.scholarrock.com/news-releases/news-release-details/scholar-rock-reports-second-quarter-2026-financial-results-and",
          "sameDateDifferentWording": true
        },
        {
          "kind": "Wording changed",
          "statement": "A Phase 1 study evaluating SRK-439 in healthy volunteers is progressing well with topline data anticipated in late 2026.",
          "window": "in late 2026",
          "documentType": "SEC Exhibit 99.1",
          "date": "2026-08-06",
          "dateBasis": "filing_date",
          "url": "https://www.sec.gov/Archives/edgar/data/1727196/000119312526336715/srrk-ex99_1.htm",
          "sameDateDifferentWording": true
        },
        {
          "kind": "Statement retained",
          "statement": "A Phase 1 study of SRK-439 in healthy volunteers is currently underway, with topline data anticipated in the second half of 2026.",
          "window": "in the second half of 2026",
          "documentType": "SEC Form 10-Q",
          "date": "2026-08-06",
          "dateBasis": "filing_date",
          "url": "https://www.sec.gov/Archives/edgar/data/1727196/000119312526336732/srrk-20260630.htm",
          "sameDateDifferentWording": true
        }
      ],
      "disclosure": null,
      "wordingChanges": [
        {
          "date": "2026-08-06",
          "fromSources": [
            {
              "statement": "A Phase 1 study evaluating SRK-439 in healthy volunteers is underway, with topline data expected in the second half of 2026.",
              "window": "in the second half of 2026",
              "documentType": "SEC Exhibit 99.1",
              "date": "2026-05-07",
              "dateBasis": "filing_date",
              "url": "https://www.sec.gov/Archives/edgar/data/1727196/000110465926056655/srrk-20260507xex99d1.htm"
            },
            {
              "statement": "A Phase 1 study of SRK-439 in healthy volunteers is currently underway, with topline data anticipated in the second half of 2026.",
              "window": "in the second half of 2026",
              "documentType": "SEC Form 10-Q",
              "date": "2026-05-07",
              "dateBasis": "filing_date",
              "url": "https://www.sec.gov/Archives/edgar/data/1727196/000110465926056667/srrk-20260331x10q.htm"
            }
          ],
          "toSources": [
            {
              "statement": "A Phase 1 study evaluating SRK-439 in healthy volunteers is progressing well with topline data anticipated in late 2026.",
              "window": "in late 2026",
              "documentType": "Company press release",
              "date": "2026-08-06",
              "dateBasis": "company_release",
              "url": "https://investors.scholarrock.com/news-releases/news-release-details/scholar-rock-reports-second-quarter-2026-financial-results-and"
            },
            {
              "statement": "A Phase 1 study evaluating SRK-439 in healthy volunteers is progressing well with topline data anticipated in late 2026.",
              "window": "in late 2026",
              "documentType": "SEC Exhibit 99.1",
              "date": "2026-08-06",
              "dateBasis": "filing_date",
              "url": "https://www.sec.gov/Archives/edgar/data/1727196/000119312526336715/srrk-ex99_1.htm"
            }
          ]
        }
      ],
      "additionalDisclosures": [],
      "scopeNotes": [
        "The initial entry means the earliest wording located within the sources checked; an exhaustive history is not asserted.",
        "Company timing wording is retained. A newer corporate release about another program does not establish a results announcement for this trial.",
        "Additional source review: 2026-10-10. Earlier retained sources were reviewed on 2026-10-09; their original source-check dates and scopes are retained.",
        "The August 6 Form 10-Q covers the quarter ended June 30, 2026."
      ],
      "scopeSources": [],
      "companyReleases": [
        {
          "date": "2026-08-06",
          "url": "https://investors.scholarrock.com/news-releases/news-release-details/scholar-rock-reports-second-quarter-2026-financial-results-and"
        },
        {
          "date": "2026-10-08",
          "url": "https://investors.scholarrock.com/news-releases/news-release-details/scholar-rock-resubmits-apitegromab-marketing-authorisation"
        }
      ],
      "companySourceChecks": [
        {
          "url": "https://investors.scholarrock.com/investors-media/press-releases",
          "checkedDate": "2026-10-09",
          "label": "Company press release listing"
        }
      ],
      "secCheckedThrough": "2026-08-06",
      "secScope": "8-K and Ex-99.1 1/12, 3/3 (incl. 8-K/A), 5/7, 10-Q 5/7, 8-K and Ex-99.1 8/6 checked against originals. Later SEC filings not searched. Supplement reviewed 2026-10-10: selected 2026-08-06 SEC Form 10-Q timing occurrences. This is not an exhaustive later-filing search.",
      "companyPrCheckedDate": "2026-10-09",
      "companyPrScope": "Press releases page 1 checked on 10/9; Oct 8 release is apitegromab MAA, not SRK-439.",
      "founderCheckedDate": "2026-10-10",
      "rowsShown": 1,
      "rowsTotal": 1,
      "citation": "Scholar Rock (SRRK) — SRK-439 · topline data: “in H2 2026” (SEC Exhibit 99.1 2026-01-12); statement retained “in the second half of 2026” (2026-03-03); statement retained “in the second half of 2026” (2026-05-07); statement retained “in the second half of 2026” (2026-05-07); wording changed from “in the second half of 2026” (2026-05-07) and “in the second half of 2026” (2026-05-07) to “in late 2026” (2026-08-06); wording changed from “in the second half of 2026” (2026-05-07) and “in the second half of 2026” (2026-05-07) to “in late 2026” (2026-08-06); statement retained “in the second half of 2026” (2026-08-06). Status Window open, checked 2026-10-10. Sources: https://www.sec.gov/Archives/edgar/data/1727196/000110465926002757/srrk-20260112xex99d1.htm | https://www.sec.gov/Archives/edgar/data/1727196/000110465926022547/srrk-20260303xex99d1.htm | https://www.sec.gov/Archives/edgar/data/1727196/000110465926056655/srrk-20260507xex99d1.htm | https://www.sec.gov/Archives/edgar/data/1727196/000110465926056667/srrk-20260331x10q.htm | https://investors.scholarrock.com/news-releases/news-release-details/scholar-rock-reports-second-quarter-2026-financial-results-and | https://www.sec.gov/Archives/edgar/data/1727196/000119312526336715/srrk-ex99_1.htm | https://www.sec.gov/Archives/edgar/data/1727196/000119312526336732/srrk-20260630.htm",
      "corrections": [
        {
          "date": "2026-10-09",
          "what": "Display rule corrected — equivalent timing phrases (e.g., 'H2 2026' / 'second half of 2026') are now shown as Statement retained. Source quotes and status unchanged.",
          "why": "Equivalent timing notation is compared after normalization.",
          "evidence": "Founder approved the normalization correction and this exact public line in this chat on 2026-10-09.",
          "displayOnly": true
        },
        {
          "date": "2026-10-10",
          "what": "Added previously omitted 2026-08-06 SEC Form 10-Q timing source.",
          "why": "Selected-source supplement following founder review; prior rows retained.",
          "evidence": "https://www.sec.gov/Archives/edgar/data/1727196/000119312526336732/srrk-20260630.htm"
        }
      ]
    }
  ]
}